{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:08:17Z","timestamp":1762459697255,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-018-5224-6","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:51:16Z","timestamp":1546822276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study"],"prefix":"10.1186","volume":"19","author":[{"given":"Yoshihiko","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel H.","family":"Bair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"5224_CR1","unstructured":"Inlyta\u00ae (axitinib) US prescribing information. Pfizer Inc, New York, NY. Pfizer Inc. 2014. \n                    http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=759\n                    \n                  . Accessed 20 July 2017."},{"issue":"12","key":"5224_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","volume":"14","author":"BI Rini","year":"2013","unstructured":"Rini BI, Melichar B, Ueda T, Grunwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233\u201342.","journal-title":"Lancet Oncol."},{"issue":"6","key":"5224_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.clgc.2016.04.005","volume":"14","author":"BI Rini","year":"2016","unstructured":"Rini BI, Tomita Y, Melichar B, Ueda T, Grunwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. Clin Genitourin Cancer. 2016;14(6):499\u2013503.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"5224_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"R Motzer","year":"2002","unstructured":"Motzer R, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289\u201396.","journal-title":"J Clin Oncol"},{"issue":"34","key":"5224_CR5","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5224_CR6","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1038\/bjc.2013.236","volume":"108","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E, Gore ME. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108(12):2470\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"5224_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DY Heng","year":"2013","unstructured":"Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141\u20138.","journal-title":"Lancet Oncol"},{"issue":"11","key":"5224_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jjco\/hyw103","volume":"46","author":"Y Tomita","year":"2016","unstructured":"Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, Naito S, Akaza H. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol. 2016;46(11):1031\u201341.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"5224_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/cas.13232","volume":"108","author":"M Oya","year":"2017","unstructured":"Oya M, Tomita Y, Fukasawa S, Shinohara N, Habuchi T, Rini BI, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Uemura H. Overall survival of 1st-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. Cancer Sci. 2017;108(6):1231\u20139.","journal-title":"Cancer Sci"},{"issue":"6","key":"5224_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552\u201362.","journal-title":"Lancet Oncol."},{"issue":"2","key":"5224_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2008.12.026","volume":"57","author":"S Naito","year":"2010","unstructured":"Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Tomita Y. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 2010;57(2):317\u201325.","journal-title":"Eur Urol"},{"issue":"1","key":"5224_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/bju.12494","volume":"114","author":"B Beuselinck","year":"2014","unstructured":"Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schoffski P. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 2014;114(1):81\u20139.","journal-title":"BJU Int"},{"issue":"2","key":"5224_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3892\/ol.2014.2207","volume":"8","author":"J Teishima","year":"2014","unstructured":"Teishima J, Kobatake K, Hayashi T, Seno Y, Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, Kobayashi K, Ohara S, Kajiwara M, Matsubara A. Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncol Lett. 2014;8(2):881\u20135.","journal-title":"Oncol Lett"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5224-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5224-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5224-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T19:08:37Z","timestamp":1578337717000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5224-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5224"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5224-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"11 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The study protocol and patient informed consent form were approved by the institutional review board or independent ethics committee at each centre. The institutional review boards or independent ethics committees included Eticka komise, Multicenticka eticka komise Fakultni nemocnice Olomouc, Eticka komise Fakultni nemocnice Na Bulovce, Eticka komise, and Masarykuv onkologicky usta y (Czech Republic); Ethikkommission des Fachbereichs Medizin der Johann Wolfgang (Germany); Yamagata University Hospital IRB, Kinki University Hospital IRB, Keio University Hospital IRB, Tokushima University Hospital IRB, Kyushu University Hospital IRB, Sapporo Medical University Hospital IRB, Hokkaido University Hospital IRB, Chiba Cancer Centre IRB, Hamamatsu University School of Medicine, University Hospital IRB, Kobe University Hospital IRB, Nagoya University Hospital IRB, Akita University Hospital IRB, Japanese Foundation For Cancer Research Cancer Institute Hospital IRB, National Cancer Centre IRB, and Nagasaki University Hospital IRB (Japan); Ethics Council at the Ministry of Healthcare and Social Development of Russian Federation, Local Ethics Committee at Russian Research Centre of Roentgenology and Radiology, Ethics Committee, Russian Oncological Research Centre n.a. Blokhin RAMS, Ethics Committee at Samara Regional Clinical Oncology Dispensary, Local ethical committee Institution of Russian Academy of Medical Sciences Medical Radiology Research Centre of RAMS, Ethics Committee Leningrad Regional Oncology Dispensary, Ethics Committee at the City Clinical Oncology Dispensary of Saint- Petersburg, and Ethics Committee at the Federal Service on Surveillance in Healthcare and Social Development (Russian Federation); CEIC AREA 5-Hospital Universitario La Paz Ethics Committee of Clinic Hospital General, Hospital Gregorio Mara\u00f1on Comite Etico de Investigacion Clinica, and Hospital Universitario La Paz Ethics Committee of Clinic Investigation (Spain); Nebraska Methodist Hospital Institutional Review Board, Office for Human Research Studies Dana Farber Cancer Institute, Cleveland Clinic Institutional Review Board, University of Nebraska Medical Centre Institutional Review Board, The Johns Hopkins Medicine Institutional Review Board, Quorurn Review, Schulman Associates Institutional Review Board, Inc., IUPUI Institutional Review Board, Indiana University Institutional Review Board, Western Institutional Review Board, Washington University School of Medicine Human Research Protection Office\u00a0(IRB), University of Texas M.D. Anderson Cancer Centre Surveillance Committee FWA-363, Oregon Health and Science University Research Integrity Office (ORIO) Institutional Review Board, and University of Cincinnati Institutional Review Board (USA). Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable since the manuscript does not contain any individual patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YT has received research funding from Pfizer, Ono, Takeda and Astellas, and honoraria from Pfizer, Novartis, Ono, Astellas and Bristol-Myers Squibb. HU has received research funding from Pfizer and Novartis, and honoraria from Pfizer, Bayer, Novartis, Ono and Bristol-Myers Squibb. MO has received research funding and honoraria from Pfizer, Novartis and Ono, and honoraria from Bayer. NS has received research funding from Pfizer, Ono and Astellas, and honoraria from Pfizer, Bayer, Novartis and GlaxoSmithKline. TH has received research funding and honoraria from Pfizer, Novartis and Bayer. YF, YK, and YU are employed by Pfizer R&D\u00a0Japan and YU owns stock in Pfizer. AHB is employed by and owns stock in Pfizer. BIR has served as a consultant for and received research funding from Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"17"}}